Kymera Therapeutics (NASDAQ:KYMR) Trading Up 8.3% – Still a Buy?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s stock price was up 8.3% during trading on Friday . The stock traded as high as $24.16 and last traded at $24.27. Approximately 394,641 shares were traded during mid-day trading, a decline of 28% from the average daily volume of 546,864 shares. The stock had previously closed at $22.40.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on KYMR. Citigroup initiated coverage on Kymera Therapeutics in a report on Thursday, March 13th. They set a “buy” rating and a $52.00 price target on the stock. HC Wainwright boosted their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Stephens reissued an “overweight” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, Leerink Partners restated an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Friday, December 27th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $56.36.

Kymera Therapeutics Price Performance

The stock has a market capitalization of $1.57 billion, a P/E ratio of -10.31 and a beta of 2.22. The stock’s fifty day moving average is $31.91 and its two-hundred day moving average is $39.95.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the transaction, the chief operating officer now directly owns 67,800 shares of the company’s stock, valued at $2,064,510. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,659 shares of company stock worth $324,567. Company insiders own 15.82% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Blue Trust Inc. boosted its position in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after acquiring an additional 270 shares during the period. Summit Investment Advisors Inc. boosted its holdings in shares of Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock worth $198,000 after purchasing an additional 406 shares during the period. Harbor Capital Advisors Inc. grew its position in Kymera Therapeutics by 1.7% during the fourth quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock valued at $1,649,000 after purchasing an additional 684 shares in the last quarter. KBC Group NV increased its stake in Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after buying an additional 752 shares during the period. Finally, State of Wyoming purchased a new stake in Kymera Therapeutics in the 4th quarter worth approximately $45,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.